Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB

Open source

DOI: 10.1016/s1470-2045(15)00363-0
Published: 2015 Dec
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-15-00363-0,
  title = {Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.},
  author = {Place AE and Stevenson KE and Vrooman LM and Harris MH and Hunt SK and O'Brien JE and Supko JG and Asselin BL and Athale UH and Clavell LA and Cole PD and Kelly KM and Laverdiere C and Leclerc JM and Michon B and Schorin MA and Welch JJ and Lipshultz SE and Kutok JL and Blonquist TM and Neuberg DS and Sallan SE and Silverman LB},
  year = {2015},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(15)00363-0},
  url = {https://doi.org/10.1016/s1470-2045(15)00363-0}
}

RIS

TY  - JOUR
TI  - Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
AU  - Place AE
AU  - Stevenson KE
AU  - Vrooman LM
AU  - Harris MH
AU  - Hunt SK
AU  - O'Brien JE
AU  - Supko JG
AU  - Asselin BL
AU  - Athale UH
AU  - Clavell LA
AU  - Cole PD
AU  - Kelly KM
AU  - Laverdiere C
AU  - Leclerc JM
AU  - Michon B
AU  - Schorin MA
AU  - Welch JJ
AU  - Lipshultz SE
AU  - Kutok JL
AU  - Blonquist TM
AU  - Neuberg DS
AU  - Sallan SE
AU  - Silverman LB
PY  - 2015
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(15)00363-0
UR  - https://doi.org/10.1016/s1470-2045(15)00363-0
ER  -

APA

AE, P., KE, S., LM, V., MH, H., SK, H., JE, O., JG, S., BL, A., UH, A., LA, C., PD, C., KM, K., C, L., JM, L., B, M., MA, S., JJ, W., SE, L., JL, K., TM, B., DS, N., SE, S., & LB, S. (2015). Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(15)00363-0

Source records

pubmed · retrieved 2026-09-26T23:56:55.361Z